AstraZeneca PLC is trying to take a leadership role within the biopharmaceutical sector on the issue of reducing greenhouse gas emissions, with a new initiative to convert all of its US facilities to renewable natural gas, i.e., biogas, by 2026, with greater carbon-reduction goals set for 2030 and 2045. The large pharma is partnering with Vanguard Renewables on the effort and said its suppliers and contractors will need to play a role in achieving the longer-term goals.
AstraZeneca Looks To Take Sector Lead In Reducing Greenhouse Gas Emissions
Via a partnership with Vanguard Renewables, AstraZeneca is converting its US locations to renewable natural gas, part of a goal to achieve net zero for carbon emissions by 2045.
More from ESG
• By
Parexel's CEO Peyton Howell and India boss Sanjay Vyas talk to Scrip about the value of clinical trial diversity, AI pilots underway and opportunities for India amid geopolitical rumblings, as well as the need for standardized regulatory approaches to enhance sponsor interest.
• By
A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.
• By
In an interview with JB CEO Nikhil Chopra, Scrip discusses talk of a stake sale by private equity fund KKR, gains from acquisitions including select Novartis brands, plans to ascend to the top five in cardiology and a ramp up of the CDMO business, which has clients including J&J.
• By
Congratulations to the winners of the 2024 Citeline Awards, held 8 May in Boston.
More from Scrip
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.